$2.47
+0.17 (+7.39%)
Open$2.29
Previous Close$2.30
Day High$2.49
Day Low$2.22
52W High$3.43
52W Low$0.41
Volume—
Avg Volume286.8K
Market Cap147.11M
P/E Ratio—
EPS$-0.61
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+463.2% upside
Current
$2.47
$2.47
Target
$13.91
$13.91
$12.64
$13.91 avg
$18.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.04M | 7.06M | 6.30M |
| Net Income | 1.07M | 1.40M | 1.10M |
| Profit Margin | 15.2% | 19.8% | 17.5% |
| EBITDA | 1.93M | 2.06M | 1.69M |
| Free Cash Flow | 1.16M | 752.4K | 1.14M |
| Rev Growth | -2.7% | +19.8% | -1.2% |
| Debt/Equity | 1.45 | 1.09 | 1.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |